Levodopa Incorporation in Alginate Membranes for Drug Delivery Studies

Abstract:

Parkinsons Disease (PD) is the second most common progressive neurodegenerative disorder and is referred as a leading cause of neurologic disability. The symptoms and signs of PD result from a decrease of dopamines level in the basal ganglia. Accordingly to this, exogenous substitution with dopamine agonists like levodopa, is used to correct the mechanical disorders at the early stages of the disease. Levodopa is referred as a standard in the treatment of PD. The modern studies of PD drug development and experimental therapeutics focuses on the concept of slowing and targeting the release of levodopa to prolong the therapeutic effect and reduce the number of administrations. The transdermal route was thought to be the best route for providing a progressive supply of levodopa to the systemic circulation. Alginate was chosen as a drug carrier because of its biocompatible and biodegradable properties and also because it has been widely used in drug delivery systems (DDS). The aim of this research work was to produce alginate membranes with and without levodopa. A solvent casting based methodology was used. Calcium chloride was assayed as crosslinking agent. Membranes were characterized using Differential Scanning Calorimetry (DSC) techniques. Drug release was evaluated using UV Spectrophotometry.

• Periodical: Advanced Materials Research (Volume 749)
• Pages: 423-428
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.749.423
• Online since: August 2013
• Authors: Margarida C. Franco, Tânia Viana, Sara Biscaia, Paulo Bártolo
• Keywords: Drug Delivery, Levodopa, Parkinson, Sodium Alginate

References

[1] Goole J., Amighi K.: Levodopa delivery systems for the treatment of Parkinson's Disease: an overview, International Journal of Pharmaceutics, Vol. 380, issues 1-2, pp.1-15 (2009).

DOI: 10.1016/j.ijpharm.2009.07.026

[2] Lindgren H., Cenci M., Lane E.: Dyskinesia-Advances in understanding of pathophysiology and possible treatment options, European Neurological Review, 5(2): 34-40 (2010).

[3] Pillay S.: Design and development of an implantable drug delivery polymeric scaffold for the treatment of Parkinson's disease, Master's dissertation, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (2009).

[4] Kulkarni P., Keshavayya J.: Chitosan-sodium alginate biodegradable interpenetrating polymer network (IPN) beads for delivery of ofloxacin hydrochloride, International Journal of Pharmacy and Pharmaceutical Sciences, 2 (2), pp.77-82 (2010).

[5] Filipovid-G, J., Maysinger D., Jalgenjak I.: Macromolecular prodrugs. IV. Alginate-chitosan microspheres of PHEA-L-dopa adduct, International Journal of Pharmaceutics, Vol. 116, pp.39-44 (1995).

DOI: 10.1016/0378-5173(94)00269-b

[6] Kulkarni R., Yogesh &, Wagh J.: Crosslinked alginate films as rate controlling membranes for transdermal drug delivery applications, Journal of Macromolecular Science, Part A (2010).

DOI: 10.1080/10601325.2010.483620

[7] Biscaia S.: Produção e caracterização de matrizes de alginato da alga Laminaria hyperborea para aplicação em engenharia de tecidos, Master's thesis, Escola Superior de Tecnologia e Gestão, Instituto Politécnico de Leiria (2011).

DOI: 10.21011/apn.2022.3010

[8] Viana T.: Produção de estruturas de alginato Macrocystis pyrifera e alginato-quitosano, Master's thesis, Escola Superior de Tecnologia e Gestão, Instituto Politécnico de Leiria (2011).

DOI: 10.20872/24478407/regmpe.v5n1p102-131

[9] Fwo-Long-Mi Fwu-Long Mi, Hsiang-Fa Liang, Yung-Chih Wu, Yu-Shin Lin, Ting-Fan Yang, Hsing-Wen Sunget: pH-sensitive behavior of two-component hydrogels composed of N, O-carboxymethyl chitosan and alginate, Journal Biomaterials, Science Polymer Edn, Vol. 16, nº 11, pp.1333-1345 (2005).

DOI: 10.1163/156856205774472317

[10] Saeedi M., Akbari J., Enayatifard R., Morteza-Semnani K., Tahernia M. and Valizadeh H.: In Situ Cross-Linking of Polyanionic Polymers to Sustain the Drug Release from Theophylline Tablets, Iranian Journal of Pharmaceutical Research. Vol. 8, issue 4, pp.241-249 (2009).

[11] Nokhodchi A., Tailor A.: In situ cross-linking of sodium alginate with calcium and aluminum ions to sustain the release of theophylline from polymeric matrices, Farmaco. Vol. 59, issue 12, pp.999-1004 (2004).

DOI: 10.1016/j.farmac.2004.08.006

[12] Moffat A., Osselton M., Widdop B.: Clarke's Analysis of Drugs and Poisons. Medicines Complete, The Pharmaceutical Press (2012).

[13] Kadajji V.G., Betageri G. V., Venkatesan N.: Approaches for Dissolution Testing of Novel Drug Delivery Systems, American Pharmaceutical Review. Vol. 14, issue 6 (2011).

[14] Sarmento B., Ferreira D., Veiga F., Ribeiro A.: Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies, Carbohydrate Polymers, Vol. 66, p.1–7 (2006).

DOI: 10.1016/j.carbpol.2006.02.008

[15] Gazori T., Khoshayand M., Azizi E., Yazdizade P., Nomani A., Haririan I.: Evaluation of Alginate/Chitosan nanoparticles as antisense delivery vector: Formulation, optimization and in vitro characterization, Carbohydrate Polymers, Vol. 77, p.599–606 (2009).

DOI: 10.1016/j.carbpol.2009.02.019

[16] Mulla N.: Novel sustained release formulation of levodopa-dendrimer conjugate, Master's thesis, Creighton University, Omaha (2009).

[17] US Pharmacopeia 29. NF 24, p.3050.